Zantac Carcinogen Suits Should Go to New Jersey, Plaintiffs Say

Lawsuits linking the popular antacid Zantac to the cancer-causing substance NDMA should go to New Jersey, plaintiffs in five suits said in a filing to the U.S. Judicial Panel on Multidistrict Litigation.

Defendants include Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi US Services Inc., and other companies that sold branded Zantac products.

Plaintiffs allege the manufacturers knew or should have known that Zantac exposed users to unsafe levels of the carcinogen NDMA, yet did nothing to warn consumers. Zantac metabolizes in the body to create NDMA, the plaintiffs say.

Plaintiffs in three proposed class suits seek a full refund for ...